相关实验视频
Updated: Jun 19, 2025
![An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F66708.jpg&w=3840&q=50)
10:33
An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use
Published on: May 24, 2024
746
对2013-2022财年通用药品使用费法案 (GDUFA) 计划的评估
Erica L Friedman1, Leah W Falade2, Michael G Bartlett3,4
1Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, 250 West Green Street, Athens, GA, 30602-2352, Greece.
The AAPS journal
|July 23, 2024
概括
仿制药使用者费用法案 (GDUFA) 导致仿制药批准增加了40%,第一周期批准增加了100%,证明了效率的提高. 申请撤回数量的增加也表明,仿制药计划的有效性有所提高.
科学领域:
- 制药政策 制药政策
- 药物监管 药物监管 药物监管
- 通用药物开发公司
背景情况:
- 通用药物使用费法案 (GDUFA) 成立是为了加快通用药物的批准.
- GDUFA I (2013-2017财年) 和GDUFA II (2018-2022财年) 代表了该法案的两个授权期.
- 评估GDUFA监管举措的影响对于了解仿制药市场动态至关重要.
研究的目的:
- 评估GDUFA I和GDUFA II下的监管举措的有效性.
- 分析缩写新药申请 (ANDA) 撤回和第一周期批准的趋势.
- 了解GDUFA对仿制药批准时间表和结果的影响.
主要方法:
- 从药物@FDA数据库 (2013-2022) 中分析ANDA批准数据.
- 在GDUFA I和GDUFA II期间的关键指标的比较.
- 包括诸如批准时间,剂量形式,施用途径,适应症和市场状况等因素.
主要成果:
- 与GDUFA I相比,GDUFA II的仿制药批准增加了40%以上.
- 与激励计划相关的GDUFA II的撤回申请增加了120%以上.
- 在GDUFA I和GDUFA II之间,第一轮审批数量翻了一番,这表明申请质量和审查效率有所提高.
结论:
- GDUFA显然提高了仿制药批准过程的效率和有效性.
- 激励性取消不充分的申请有助于提高第一周期批准率.
- 尽管有流行病相关的干扰,但GDUFA对仿制药的可获得性产生了积极的影响.
相关概念视频
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Drug Control Governance: Regulatory Bodies and Their Impact
149
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
149
Drug Nomenclature
1.7K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.7K
Prescription, Nonprescription and Orphan Drugs
714
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
714
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Phase II Reactions: Glucuronidation
362
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
362

